The Aspreva Effect: Canada's life sciences snagged a healthy dose of VC last year. And the IPO of Aspreva Pharmaceuticals could spawn more. -

1 June 2005•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.